Global Vaccines Market to Reach $67.91 Billion by 2030, Fueled by Innovation, Expanding Immunization Programs, and Rising Disease Burden

Vaccines Market by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, Viral Vector, mRNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, Hepatitis, MMR, RSV), Route of Administration (IM, SC, Oral)-Global Forecast to 2030
According to MarketsandMarkets Trademark , the latest research report, "Vaccines Market [https://www.marketsandmarkets.com/Market-Reports/vaccine-technologies-market-1155.html?utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr] by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, Viral Vector, mRNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, Hepatitis, MMR, RSV), Route of Administration (IM, SC, Oral) - Global Forecast to 2030," the global vaccines market (excluding COVID-19) is projected to grow from USD 47.65 billion in 2025 to USD 67.91 billion by 2030, registering a CAGR of 7.3% during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1155 [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1155&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr]

Browse

* 437 Market Data Tables
* 61 Figures
* 449 Pages and in-depth TOC on " Vaccines Market - Global Forecast to 2030".

What is driving this sustained market expansion, and why does it matter now for global decision-makers?

The growth trajectory is underpinned by increasing investments in vaccine development, alongside the continuous launch of innovative products that improve accessibility and coverage. As infectious diseases continue to pose significant global health risks, governments and healthcare organizations are prioritizing preventive strategies, thereby accelerating vaccine adoption worldwide.

How are technological advancements reshaping the competitive landscape? Breakthroughs in mRNA platforms, recombinant technologies, and advanced delivery systems are enabling faster, more efficient vaccine development. These innovations not only enhance efficacy but also reduce time-to-market, offering pharmaceutical companies and investors new avenues for value creation.

Where is demand accelerating most rapidly? Emerging markets are witnessing a surge in immunization programs, supported by global health initiatives and funding bodies. Expanded access to vaccines in these regions is playing a pivotal role in increasing overall vaccination rates, while strengthening healthcare infrastructure.

Who are the key beneficiaries of this evolving ecosystem? Governments, healthcare providers, and pharmaceutical companies are leveraging strong policy support and funding to scale immunization efforts. Additionally, organizations such as WHO, UNICEF, and Gavi are driving global vaccination campaigns, particularly in pediatric populations.

Segment Insights:

Why does pneumococcal disease dominate the market by indication? In 2024, pneumococcal vaccines accounted for the largest market share, primarily due to the high global burden of infections among children under five and elderly populations. Widespread inclusion in national immunization schedules, combined with ongoing advancements in conjugate and polysaccharide vaccines, continues to strengthen this segment's leadership.

What is fueling the rapid growth of pediatric vaccines? The pediatric segment is expected to register the fastest growth through 2030. This trend is driven by rising awareness among parents, increasing prevalence of infectious diseases in children, and the introduction of combination vaccines that reduce the number of injections. Strategic investments and large-scale immunization initiatives are further accelerating adoption across global markets.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=1155 [https://www.marketsandmarkets.com/requestsampleNew.asp?id=1155&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr]

Regional Insights:

Where does North America stand in the global landscape? In 2024, North America accounted for the largest share of the vaccines market. The region's dominance is attributed to its advanced healthcare infrastructure, strong government immunization programs, and early adoption of cutting-edge technologies such as mRNA vaccines. Robust R&D investments, favorable reimbursement frameworks, and heightened public awareness have further reinforced its leadership position.

Who are the key players shaping the future of the vaccines market?

Leading companies including Merck & Co., Inc., GSK Plc, Pfizer, Inc., Sanofi, AstraZeneca, Johnson & Johnson Services Inc., Emergent, Mitsubishi Tanabe Pharma Corporation, Serum Institute of India Pvt. Ltd, and CSL are actively investing in R&D, strategic collaborations, and product innovation to strengthen their market positions.

How will the competitive landscape evolve? With a strong development pipeline and increasing focus on therapeutic vaccines, market players are expected to unlock new growth opportunities, particularly in addressing unmet medical needs and emerging infectious diseases.

Related Reports:

Veterinary Vaccines [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1233&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr] - Global Forecast to 2030

Vaccine Adjuvants Market [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=152603894&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr] - Global Forecast to 2029

Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=global-vaccines-market-to-reach-6791-billion-by-2030-fueled-by-innovation-expanding-immunization-programs-and-rising-disease-burden]
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/vaccine-technologies-market-1155.html

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.